Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies

NCT04162756 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

Relapse/Refractory Mantle Cell Lymphoma

Interventions

BIOLOGICAL: Brexucabtagene Autoleucel (KTE-X19)
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Kite, A Gilead Company